The study compared three prenatal screening approaches for chromosomal abnormalities: genome-wide non-invasive prenatal testing (GW-NIPT), targeted NIPT and first-trimester combined testing (FCT). A model analysis of a sample of 175,000 pregnancies found that GW-NIPT diagnosed the most abnormalities – 545 cases versus 514 for targeted NIPT and 452 for FCT. The cost per diagnosed diagnosis was lowest with GW-NIPT (€152,785) compared to targeted NIPT (€159,852) and FCT (€170,050). GW-NIPT and targeted NIPT required fewer invasive procedures (both 6) than FCT (13), implying a lower risk of examination-induced miscarriage. GW-NIPT remained the most economical even with test prices up to EUR 467. The authors emphasize that implementation decisions should also take into account local prices, laboratory capacity, and availability of genetic counseling. Future research should combine screening results with long-term health and psychosocial outcomes.